Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (131-140 of 159) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activityL L Muldoon, M A Pagel, R A Kroll, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysisH A Tawbi, J H Beumer, A A Tarhini, et al.
Journal of Clinical Pharmacology|August 1, 1981
Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicinC E Riggs, M J Egorin, J Z Fuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancerD I Jodrell, M J Egorin, R M Canetta, et al.
Cancer Research|April 1, 1987
Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainageE H Oldfield, W C Clark, R L Dedrick, et al.
British Journal of Cancer|July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerC Nabhan, D Villines, T V Valdez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complexP F Dodion, D de Valeriola, N Crespeigne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B studyR C Lilenbaum, A A Miller, G Batist, et al.
Cancer Research|October 15, 1994
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor modelM J Chang, W D Yu, L M Reyno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Pageof 16

Showing results (131-140 of 159) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activityL L Muldoon, M A Pagel, R A Kroll, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysisH A Tawbi, J H Beumer, A A Tarhini, et al.
Journal of Clinical Pharmacology|August 1, 1981
Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicinC E Riggs, M J Egorin, J Z Fuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancerD I Jodrell, M J Egorin, R M Canetta, et al.
Cancer Research|April 1, 1987
Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainageE H Oldfield, W C Clark, R L Dedrick, et al.
British Journal of Cancer|July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerC Nabhan, D Villines, T V Valdez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complexP F Dodion, D de Valeriola, N Crespeigne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B studyR C Lilenbaum, A A Miller, G Batist, et al.
Cancer Research|October 15, 1994
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor modelM J Chang, W D Yu, L M Reyno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancerL M Reyno, M J Egorin, R M Canetta, et al.
Pageof 16